Darbepoetin alfa
- Generic Name
- Darbepoetin alfa
- Brand Names
- Aranesp
- Drug Type
- Biotech
- CAS Number
- 209810-58-2
- Unique Ingredient Identifier
- 15UQ94PT4P
- Background
Human erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD). Produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.
- Indication
For the treatment of anemia (from renal transplants or certain HIV treatment)
- Associated Conditions
- Anemia
A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
- First Posted Date
- 2016-09-23
- Last Posted Date
- 2019-04-02
- Lead Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Registration Number
- NCT02912494
Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)
- Conditions
- Dialysis-Dependent Chronic Kidney DiseaseAnemia
- Interventions
- First Posted Date
- 2016-09-08
- Last Posted Date
- 2022-06-28
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 3554
- Registration Number
- NCT02892149
- Locations
- 🇺🇸
AMPM Research Clinic, Miami, Florida, United States
🇬🇧Research Site, Doncaster, South Yorkshire, United Kingdom
🇺🇦Research Site #1, Cherkassy, Ukraine
Erythropoietin for Management of Anemia Caused by Chemotherapy
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- Drug: R-CHOP
- First Posted Date
- 2016-09-07
- Last Posted Date
- 2020-02-20
- Lead Sponsor
- Kosin University Gospel Hospital
- Target Recruit Count
- 53
- Registration Number
- NCT02890602
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)
- Conditions
- Anaemia
- Interventions
- First Posted Date
- 2016-08-24
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 3872
- Registration Number
- NCT02876835
- Locations
- 🇻🇳
GSK Investigational Site, Ho Chi Minh, Vietnam
Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)
- Conditions
- Dialysis-Dependent Chronic Kidney DiseaseAnemia
- Interventions
- First Posted Date
- 2016-08-15
- Last Posted Date
- 2022-07-18
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 369
- Registration Number
- NCT02865850
- Locations
- 🇺🇦
Research Site, Zhytomyr, Ukraine
🇺🇸Research Site #1, Chattanooga, Tennessee, United States
🇷🇺Research Site #2, Kemerovo, Russian Federation
Cost Comparison Study of Darbepoetin Versus Epoetin Therapy to Treat Anemia in Hemodialysis Patients
- Conditions
- AnemiaChronic Kidney Disease
- Interventions
- First Posted Date
- 2016-06-29
- Last Posted Date
- 2019-09-10
- Lead Sponsor
- Andrea L Woodland
- Target Recruit Count
- 50
- Registration Number
- NCT02817555
Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)
- Conditions
- Non-Dialysis-Dependent Chronic Kidney DiseaseAnemia
- Interventions
- First Posted Date
- 2016-02-11
- Last Posted Date
- 2022-06-27
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 1725
- Registration Number
- NCT02680574
- Locations
- 🇷🇸
Research Site #3, Belgrade, Serbia
🇿🇦Research Site #1, Durban, KwaZulu-Natal, South Africa
🇿🇦Research Site #2, Durban, KwaZulu-Natal, South Africa
Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease
- Conditions
- AnemiaNon-Dialysis-Dependent Chronic Kidney Disease
- Interventions
- First Posted Date
- 2016-01-07
- Last Posted Date
- 2022-06-27
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 1751
- Registration Number
- NCT02648347
- Locations
- 🇬🇧
Research Site, Swansea, United Kingdom
🇿🇦Research Site #1, Durban, KwaZulu-Natal, South Africa
🇿🇦Research Site #2, Durban, KwaZulu-Natal, South Africa
Pharmacokinetics and Pharmacodynamics Study of BCD-066 Compared to Aranesp® in Healthy Volunteers
- First Posted Date
- 2015-07-23
- Last Posted Date
- 2016-06-14
- Lead Sponsor
- Biocad
- Target Recruit Count
- 74
- Registration Number
- NCT02506881
- Locations
- 🇷🇺
City Mariin Hospital, St. Petersburg, Russian Federation
Safety and Efficacy Study of BCD-066 Compared to Aranesp® for Anemia Treatment in Chronic Kidney Disease Patients
- Conditions
- AnemiaChronic Kidney DiseaseEnd Stage Renal Failure on Dialysis
- Interventions
- First Posted Date
- 2015-07-23
- Last Posted Date
- 2020-05-07
- Lead Sponsor
- Biocad
- Target Recruit Count
- 196
- Registration Number
- NCT02506868
- Locations
- 🇷🇺
NEFROS Ltd, Medical Centre, Krasnodar, Russian Federation
🇷🇺N.I.Pirogov City Clinical Hospital #1, Moscow, Russian Federation
🇷🇺Alyans Biomedical - Ural'skaya gruppa, Izhevsk, Russian Federation
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.